drugset / Trial / NCT04187404
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, Phase 1/2, First-In-Human study to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.
Timeline
- Start
- 2020-07-23
- Primary completion
- 2024-10-02
- Completion
- 2024-10-02
Outcome
Outcome not reported
Stopped (Business): “Strategic decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EO2401 | Vaccine | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |